NRG-GY029

A Randomized Phase II trial comparing the combination of PI3K inhibitor Copanlisib (BAY 80-6946) and PARP inhibitor Olaparib (AZD2281) to standard chemotherapy in patients with recurrent platinum resistant ovarian, fallopian tube, or primary peritoneal cancer who have progressed through prior PARP inhibitor therapy

Principal Investigator

Panos Konstantinopoulos, MD

Status

Closed to Accrual

Disease Site

Gynecologic [GY]

Ovarian

Phase

II

Developmental Therapeutics

No

Primary Objective

To assess the clinicalefficacy of the combination of copanlisib/olaparib, as measured byinvestigator-assessed progression freesurvival (PFS), compared to standard chemotherapy in the setting ofrecurrent platinum resistant ovarian cancer that has progressed through priorPARP inhibitor therapy.

Patient Population

Patients with recurrent platinum resistantovarian, fallopian tube, or primary peritoneal cancer who have progressedthrough prior PARP inhibitor therapy.

Target Accrual

96